Researchers are excited about this new drug, a innovative dual treatment showing promising results in clinical trials for body management. It acts by targeting both pathways : GLP-1 and GIP, which , when activated , support influence hunger and boost calorie burn. Initial findings indicate noteworthy size management and potential improvements for p